Tilray | TRLY - Gross Profit On Sales

Stock Price
10.72
Daily Change
-0.21 -1.92%
Monthly
0.56%
Yearly
901.87%
Q1 Forecast
10.37

Tilray reported $67.63M in Gross Profit on Sales for its fiscal quarter ending in March of 2025.





Gross Profit On Sales Change Date
Acasti Pharma USD 0 0 Mar/2022
Akebia Therapeutics USD 49.21M 13.25M Mar/2025
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
Aurora Cannabis CAD 32.29M 4.34M Sep/2025
Avita Medical AUD 14.95M 1.18M Jun/2025
Canopy Growth CAD 21.9M 3.86M Sep/2025
Cronos Group USD 16.19M 34.52M Dec/2025
Dianthus Therapeutics USD 396K 203K Sep/2025
Divis Laboratories Ltd INR 16.59B 2.05B Dec/2025
Ionis Pharmaceuticals USD 195M 40M Dec/2025
IQVIA Holdings USD 1.12B 32M Dec/2025
Knight Therapeutics CAD 44.83M 9.96M Jun/2025
Moderna USD 226M 583M Dec/2025
Organigram Holdings CAD 31.84M 23.88M Sep/2025
Organon & Co USD 854M 3M Dec/2025
Revvity USD 421.66M 47.06M Dec/2025
Tectonic Therapeutic USD 0 0 Mar/2025
Tilray USD 67.63M 15.62M Mar/2025
Viatris USD 1.15B 223.6M Dec/2025
Xeris Pharmaceuticals USD 63.38M 3.74M Sep/2025